

Gerrit Storm

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9238515/publications.pdf>

Version: 2024-02-01

398
papers

32,125
citations

2975

93
h-index

5988

160
g-index

400
all docs

400
docs citations

400
times ranked

34548
citing authors

#	ARTICLE	IF	CITATIONS
1	Endosomal escape pathways for delivery of biologicals. <i>Journal of Controlled Release</i> , 2011, 151, 220-228.	9.9	1,278
2	Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress. <i>Journal of Controlled Release</i> , 2012, 161, 175-187.	9.9	1,131
3	Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. <i>Advanced Drug Delivery Reviews</i> , 2017, 108, 25-38.	13.7	881
4	Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. <i>Nucleic Acids Research</i> , 2004, 32, e149-e149.	14.5	800
5	Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release. <i>Pharmaceutical Research</i> , 2010, 27, 2569-2589.	3.5	791
6	Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. <i>Advanced Drug Delivery Reviews</i> , 1995, 17, 31-48.	13.7	788
7	Theranostic Nanomedicine. <i>Accounts of Chemical Research</i> , 2011, 44, 1029-1038.	15.6	765
8	Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization. <i>Frontiers in Pharmacology</i> , 2018, 9, 790.	3.5	586
9	Sheddable Coatings for Long-Circulating Nanoparticles. <i>Pharmaceutical Research</i> , 2008, 25, 55-71.	3.5	510
10	Quantum Dots with a Paramagnetic Coating as a Bimodal Molecular Imaging Probe. <i>Nano Letters</i> , 2006, 6, 1-6.	9.1	477
11	Noninvasive Imaging of Nanomedicines and Nanotheranostics: Principles, Progress, and Prospects. <i>Chemical Reviews</i> , 2015, 115, 10907-10937.	47.7	401
12	Nanotheranostics and Image-Guided Drug Delivery: Current Concepts and Future Directions. <i>Molecular Pharmaceutics</i> , 2010, 7, 1899-1912.	4.6	344
13	Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status. <i>Advanced Drug Delivery Reviews</i> , 2013, 65, 1284-1298.	13.7	338
14	Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. <i>Journal of Controlled Release</i> , 2003, 91, 115-122.	9.9	298
15	Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery. <i>Journal of Controlled Release</i> , 2005, 103, 341-353.	9.9	286
16	Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. <i>Arthritis and Rheumatism</i> , 2003, 48, 2059-2066.	6.7	281
17	Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications. <i>Current Opinion in Biotechnology</i> , 2013, 24, 1159-1166.	6.6	279
18	Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes. <i>International Journal of Pharmaceutics</i> , 2011, 416, 433-442.	5.2	278

#	ARTICLE	IF	CITATIONS
19	Passive versus Active Tumor Targeting Using RGD- and NGR-Modified Polymeric Nanomedicines. <i>Nano Letters</i> , 2014, 14, 972-981.	9.1	272
20	The battle of "nano" paclitaxel. <i>Advanced Drug Delivery Reviews</i> , 2017, 122, 20-30.	13.7	270
21	MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. <i>FASEB Journal</i> , 2005, 19, 2008-2010.	0.5	247
22	Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin. <i>Biomaterials</i> , 2010, 31, 7797-7804.	11.4	241
23	The role of liposomes in clinical nanomedicine development. What now? Now what?. <i>Journal of Controlled Release</i> , 2020, 318, 256-263.	9.9	226
24	Multidrug resistance: Physiological principles and nanomedical solutions. <i>Advanced Drug Delivery Reviews</i> , 2013, 65, 1852-1865.	13.7	220
25	Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. <i>Biomaterials</i> , 2009, 30, 3466-3475.	11.4	219
26	A Liposomal System for Contrast-Enhanced Magnetic Resonance Imaging of Molecular Targets. <i>Bioconjugate Chemistry</i> , 2004, 15, 799-806.	3.6	216
27	Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities. <i>Journal of Controlled Release</i> , 2018, 277, 1-13.	9.9	214
28	Strategies for encapsulation of small hydrophilic and amphiphilic drugs in PLGA microspheres: State-of-the-art and challenges. <i>International Journal of Pharmaceutics</i> , 2016, 499, 358-367.	5.2	207
29	Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2000, 43, 1951-1959.	6.7	198
30	Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors. <i>Advanced Drug Delivery Reviews</i> , 2017, 119, 44-60.	13.7	194
31	Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. <i>Brain</i> , 2003, 126, 1895-1904.	7.6	190
32	Superparamagnetic Iron Oxide Nanoparticles Encapsulated in Biodegradable Thermosensitive Polymeric Micelles: Toward a Targeted Nanomedicine Suitable for Image-Guided Drug Delivery. <i>Langmuir</i> , 2009, 25, 2060-2067.	3.5	187
33	Complete Regression of Xenograft Tumors upon Targeted Delivery of Paclitaxel <i>via</i> \uparrow Stacking Stabilized Polymeric Micelles. <i>ACS Nano</i> , 2015, 9, 3740-3752.	14.6	185
34	Multifunctional Nanoemulsion Platform for Imaging Guided Therapy Evaluated in Experimental Cancer. <i>ACS Nano</i> , 2011, 5, 4422-4433.	14.6	183
35	Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. <i>Vaccine</i> , 2004, 22, 1903-1913.	3.8	181
36	Targeting tumor antigens to dendritic cells using particulate carriers. <i>Journal of Controlled Release</i> , 2012, 161, 25-37.	9.9	174

#	ARTICLE	IF	CITATIONS
37	Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation. <i>Science Advances</i> , 2015, 1, .	10.3	173
38	Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain. <i>Journal of Controlled Release</i> , 2011, 150, 30-36.	9.9	171
39	A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- β 2-microglobulin-/- double-mutant mice. <i>Blood</i> , 2003, 102, 2522-2531.	1.4	168
40	Personalized Nanomedicine. <i>Clinical Cancer Research</i> , 2012, 18, 4889-4894.	7.0	166
41	Liposomes: quo vadis?. <i>Pharmaceutical Science & Technology Today</i> , 1998, 1, 19-31.	0.7	164
42	Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 1198-1208.	6.7	164
43	Immunoliposomes for the targeted delivery of antitumor drugs. <i>Advanced Drug Delivery Reviews</i> , 1999, 40, 103-127.	13.7	163
44	Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells. <i>Journal of Controlled Release</i> , 2012, 160, 88-95.	9.9	158
45	Functional Characterization of an Endosome-disruptive Peptide and Its Application in Cytosolic Delivery of Immunoliposome-entrapped Proteins. <i>Journal of Biological Chemistry</i> , 2002, 277, 27135-27143.	3.4	157
46	Cancer nanomedicine: is targeting our target?. <i>Nature Reviews Materials</i> , 2016, 1, .	48.7	154
47	Targeting Anti-Transferrin Receptor Antibody (OX26) and OX26-Conjugated Liposomes to Brain Capillary Endothelial Cells Using In Situ Perfusion. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2004, 24, 1193-1204.	4.3	146
48	Bioinspired Cell-Derived Nanovesicles versus Exosomes as Drug Delivery Systems: a Cost-Effective Alternative. <i>Scientific Reports</i> , 2017, 7, 14322.	3.3	146
49	Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes. <i>International Journal of Pharmaceutics</i> , 2007, 331, 211-214.	5.2	145
50	Integrins in wound healing, fibrosis and tumor stroma: High potential targets for therapeutics and drug delivery. <i>Advanced Drug Delivery Reviews</i> , 2018, 129, 37-53.	13.7	145
51	Multimodal Clinical Imaging To Longitudinally Assess a Nanomedical Anti-Inflammatory Treatment in Experimental Atherosclerosis. <i>Molecular Pharmaceutics</i> , 2010, 7, 2020-2029.	4.6	144
52	Annexin A5-Conjugated Quantum Dots with a Paramagnetic Lipidic Coating for the Multimodal Detection of Apoptotic Cells. <i>Bioconjugate Chemistry</i> , 2006, 17, 865-868.	3.6	141
53	A Novel Family of Amino Acid-Based Biodegradable Polymer-Lipid Conjugates for the Development of Long-Circulating Liposomes with Effective Drug-Targeting Capacity. <i>Bioconjugate Chemistry</i> , 2003, 14, 1156-1164.	3.6	140
54	Molecular imaging of tumor angiogenesis using α v β 3-integrin targeted multimodal quantum dots. <i>Angiogenesis</i> , 2009, 12, 17-24.	7.2	139

#	ARTICLE	IF	CITATIONS
55	Dexamethasone nanomedicines for COVID-19. <i>Nature Nanotechnology</i> , 2020, 15, 622-624.	31.5	138
56	Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies. <i>Journal of Antimicrobial Chemotherapy</i> , 2001, 48, 333-344.	3.0	135
57	Targeting the Stat6 pathway in tumor-associated macrophages reduces tumor growth and metastatic niche formation in breast cancer. <i>FASEB Journal</i> , 2018, 32, 969-978.	0.5	134
58	Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis. <i>Arthritis and Rheumatism</i> , 2005, 52, 1314-1318.	6.7	133
59	Image-guided, targeted and triggered drug delivery to tumors using polymer-based microbubbles. <i>Journal of Controlled Release</i> , 2012, 163, 75-81.	9.9	133
60	Nanomedicines for Inflammatory Arthritis: Head-to-Head Comparison of Glucocorticoid-Containing Polymers, Micelles, and Liposomes. <i>ACS Nano</i> , 2014, 8, 458-466.	14.6	133
61	Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 1039-1046.	3.3	127
62	Polymeric nanomedicines for image-guided drug delivery and tumor-targeted combination therapy. <i>Nano Today</i> , 2010, 5, 197-212.	11.9	126
63	Effect of physicochemical modification on the biodistribution and tumor accumulation of HPMA copolymers. <i>Journal of Controlled Release</i> , 2005, 110, 103-118.	9.9	125
64	Physicochemical Strategies to Enhance Stability and Drug Retention of Polymeric Micelles for Tumor-Targeted Drug Delivery. <i>Macromolecular Bioscience</i> , 2017, 17, 1600160.	4.1	125
65	Nanomedicines as Cancer Therapeutics: Current Status. <i>Current Cancer Drug Targets</i> , 2013, 13, 362-378.	1.6	123
66	Theranostic USPIO-Loaded Microbubbles for Mediating and Monitoring Blood-Brain Barrier Permeation. <i>Advanced Functional Materials</i> , 2015, 25, 36-43.	14.9	123
67	Ultrasound-mediated drug delivery to the brain: principles, progress and prospects. <i>Drug Discovery Today: Technologies</i> , 2016, 20, 41-48.	4.0	120
68	Tumor stroma-containing 3D spheroid arrays: A tool to study nanoparticle penetration. <i>Journal of Controlled Release</i> , 2016, 244, 257-268.	9.9	119
69	Sonoporation enhances liposome accumulation and penetration in tumors with low EPR. <i>Journal of Controlled Release</i> , 2016, 231, 77-85.	9.9	119
70	Annexin A5-Functionalized Bimodal Lipid-Based Contrast Agents for the Detection of Apoptosis. <i>Bioconjugate Chemistry</i> , 2006, 17, 741-749.	3.6	117
71	Downregulation of EGFR by a novel multivalent nanobody-liposome platform. <i>Journal of Controlled Release</i> , 2010, 145, 165-175.	9.9	117
72	SiRNA delivery with functionalized carbon nanotubes. <i>International Journal of Pharmaceutics</i> , 2011, 416, 419-425.	5.2	117

#	ARTICLE	IF	CITATIONS
73	Fluorescent cell-traceable dexamethasone-loaded liposomes for the treatment of inflammatory liver diseases. <i>Biomaterials</i> , 2015, 37, 367-382.	11.4	115
74	Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy. <i>Biomaterials</i> , 2013, 34, 1255-1260.	11.4	111
75	In Vivo Methods to Study Uptake of Nanoparticles into the Brain. <i>Pharmaceutical Research</i> , 2011, 28, 456-471.	3.5	110
76	Effect of radiotherapy and hyperthermia on the tumor accumulation of HPMA copolymer-based drug delivery systems. <i>Journal of Controlled Release</i> , 2007, 117, 333-341.	9.9	109
77	MicroRNA Targeting to Modulate Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2016, 6, 3.	2.8	108
78	Liposomal Drug Formulations in the Treatment of Rheumatoid Arthritis. <i>Molecular Pharmaceutics</i> , 2011, 8, 1002-1015.	4.6	107
79	Atherosclerotic Plaque Targeting Mechanism of Long-Circulating Nanoparticles Established by Multimodal Imaging. <i>ACS Nano</i> , 2015, 9, 1837-1847.	14.6	105
80	Systemic miRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma. <i>Oncotarget</i> , 2014, 5, 6687-6700.	1.8	105
81	In vivo nanotoxicity testing using the zebrafish embryo assay. <i>Journal of Materials Chemistry B</i> , 2013, 1, 3918.	5.8	104
82	Enhancing photodynamic therapy of refractory solid cancers: Combining second-generation photosensitizers with multi-targeted liposomal delivery. <i>Journal of Photochemistry and Photobiology C: Photochemistry Reviews</i> , 2015, 23, 103-131.	11.6	104
83	Liposome encapsulated berberine treatment attenuates cardiac dysfunction after myocardial infarction. <i>Journal of Controlled Release</i> , 2017, 247, 127-133.	9.9	104
84	Effect of Intratumoral Injection on the Biodistribution, the Therapeutic Potential of HPMA Copolymer-Based Drug Delivery Systems. <i>Neoplasia</i> , 2006, 8, 788-795.	5.3	103
85	Superoxide dismutase entrapped in long-circulating liposomes: formulation design and therapeutic activity in rat adjuvant arthritis. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2002, 1564, 227-236.	2.6	102
86	Liposomes in the treatment of inflammatory disorders. <i>Expert Opinion on Drug Delivery</i> , 2005, 2, 465-476.	5.0	102
87	Glucocorticoid-Loaded Core-Cross-Linked Polymeric Micelles with Tailorable Release Kinetics for Targeted Therapy of Rheumatoid Arthritis. <i>Angewandte Chemie - International Edition</i> , 2012, 51, 7254-7258.	13.8	102
88	Noninvasive Optical Imaging of Nanomedicine Biodistribution. <i>ACS Nano</i> , 2013, 7, 252-262.	14.6	102
89	Intravenous administration of superoxide dismutase entrapped in long circulating liposomes. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1999, 1419, 325-334.	2.6	101
90	Nanotechnological approaches for the delivery of macromolecules. <i>Journal of Controlled Release</i> , 2003, 87, 81-88.	9.9	101

#	ARTICLE	IF	CITATIONS
91	OVCAR-3 cells internalize TAT-peptide modified liposomes by endocytosis. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2004, 1665, 48-56.	2.6	101
92	Effect of cationic carriers on the pharmacokinetics and tumor localization of nucleic acids after intravenous administration. <i>International Journal of Pharmaceutics</i> , 2007, 331, 167-175.	5.2	101
93	Liposome-Encapsulated Prednisolone Phosphate Inhibits Growth of Established Tumors in Mice. <i>Neoplasia</i> , 2005, 7, 118-127.	5.3	99
94	Immune cell screening of a nanoparticle library improves atherosclerosis therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E6731-E6740.	7.1	95
95	Nanobody "Shell" functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting. <i>Journal of Controlled Release</i> , 2011, 151, 183-192.	9.9	94
96	Extracellular vesicles as a drug delivery system: A systematic review of preclinical studies. <i>Advanced Drug Delivery Reviews</i> , 2021, 175, 113801.	13.7	92
97	Drug targeting systems for inflammatory disease: One for all, all for one. <i>Journal of Controlled Release</i> , 2012, 161, 225-234.	9.9	88
98	Complete regression of breast tumour with a single dose of docetaxel-entrapped core-cross-linked polymeric micelles. <i>Biomaterials</i> , 2015, 53, 370-378.	11.4	88
99	Nano-targeted relaxin impairs fibrosis and tumor growth in pancreatic cancer and improves the efficacy of gemcitabine in vivo. <i>Journal of Controlled Release</i> , 2018, 290, 1-10.	9.9	88
100	Effects of Physicochemical Characteristics of Poly(2-(dimethylamino)ethyl methacrylate)-Based Polyplexes on Cellular Association and Internalization. <i>Journal of Drug Targeting</i> , 2000, 8, 51-66.	4.4	87
101	Betulinic acid delivered in liposomes reduces growth of human lung and colon cancers in mice without causing systemic toxicity. <i>Anti-Cancer Drugs</i> , 2011, 22, 223-233.	1.4	87
102	Photochemical internalization enhances silencing of epidermal growth factor receptor through improved endosomal escape of siRNA. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2007, 1768, 1211-1217.	2.6	86
103	Sonochemotherapy: from bench to bedside. <i>Frontiers in Pharmacology</i> , 2015, 6, 138.	3.5	84
104	Lymphatic uptake and biodistribution of liposomes after subcutaneous injection: III. Influence of surface modification with poly(ethyleneglycol). , 1997, 14, 1479-1484.		83
105	Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment. <i>Journal of Controlled Release</i> , 2012, 159, 281-289.	9.9	83
106	Characterizing EPR-mediated passive drug targeting using contrast-enhanced functional ultrasound imaging. <i>Journal of Controlled Release</i> , 2014, 182, 83-89.	9.9	83
107	Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. <i>FASEB Journal</i> , 2007, 21, 378-383.	0.5	82
108	Poly(amino acid)s: Promising enzymatically degradable stealth coatings for liposomes. <i>International Journal of Pharmaceutics</i> , 2007, 331, 186-189.	5.2	82

#	ARTICLE	IF	CITATIONS
109	Antitumor Activity of Liposomal Prednisolone Phosphate Depends on the Presence of Functional Tumor-Associated Macrophages in Tumor Tissue. <i>Neoplasia</i> , 2008, 10, 108-117.	5.3	82
110	Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs. <i>Biochemical and Biophysical Research Communications</i> , 2015, 468, 490-497.	2.1	81
111	ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancreatic cancer. <i>Science Advances</i> , 2019, 5, eaax2770.	10.3	81
112	Enhanced localization of liposomes with prolonged blood circulation time in infected lung tissue. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 1992, 1138, 318-326.	3.8	80
113	Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: Comparison of the porcine and rat responses. <i>Journal of Controlled Release</i> , 2014, 195, 2-10.	9.9	79
114	Nanomedicine Strategies to Target Tumor-Associated Macrophages. <i>International Journal of Molecular Sciences</i> , 2017, 18, 979.	4.1	79
115	Gold Nanocrystal Labeling Allows Low-Density Lipoprotein Imaging from the Subcellular to Macroscopic Level. <i>ACS Nano</i> , 2013, 7, 9761-9770.	14.6	77
116	Sonopermeation to improve drug delivery to tumors: from fundamental understanding to clinical translation. <i>Expert Opinion on Drug Delivery</i> , 2018, 15, 1249-1261.	5.0	76
117	Liposomes for scintigraphic detection of infection and inflammation. <i>Advanced Drug Delivery Reviews</i> , 1999, 37, 225-235.	13.7	75
118	Liposomes: From the Bench to the Bed. <i>Journal of Liposome Research</i> , 2003, 13, 33-36.	3.3	75
119	Liposomal corticosteroids for the treatment of inflammatory disorders and cancer. <i>Journal of Controlled Release</i> , 2014, 190, 624-636.	9.9	75
120	Transferrin-binding peptide functionalized polymersomes mediate targeted doxorubicin delivery to colorectal cancer in vivo. <i>Journal of Controlled Release</i> , 2020, 319, 407-415.	9.9	74
121	Pharmacokinetics of poly(hydroxyethyl-L-asparagine)-coated liposomes is superior over that of PEG-coated liposomes at low lipid dose and upon repeated administration. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2007, 1768, 737-743.	2.6	73
122	Inhibition of canonical WNT signaling pathway by β -catenin/CBP inhibitor ICG-001 ameliorates liver fibrosis in vivo through suppression of stromal CXCL12. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 804-818.	3.8	73
123	MicroRNA-199a and -214 as potential therapeutic targets in pancreatic stellate cells in pancreatic tumor. <i>Oncotarget</i> , 2016, 7, 16396-16408.	1.8	72
124	Prolonged systemic delivery of peptide drugs by long-circulating liposomes: illustration with vasopressin in the Brattleboro rat. <i>Pharmaceutical Research</i> , 1992, 09, 260-265.	3.5	70
125	The interplay of the Notch signaling in hepatic stellate cells and macrophages determines the fate of liver fibrogenesis. <i>Scientific Reports</i> , 2016, 5, 18272.	3.3	70
126	Nanopolymersomes with an Ultrahigh Iodine Content for High-Performance X-Ray Computed Tomography Imaging In Vivo. <i>Advanced Materials</i> , 2017, 29, 1603997.	21.0	70

#	ARTICLE	IF	CITATIONS
127	In vivo tumor transfection mediated by polyplexes based on biodegradable poly(DMAEA)-phosphazene. <i>Journal of Controlled Release</i> , 2005, 109, 275-287.	9.9	69
128	Physicochemical and Biological Evaluation of siRNA Polyplexes Based on PEGylated Poly(amido) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70	3.5	68
129	Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens. <i>Journal of Controlled Release</i> , 2015, 203, 67-76.	9.9	68
130	Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity. <i>Journal of Controlled Release</i> , 2010, 141, 234-240.	9.9	67
131	Temperature-Sensitive Poly(<i>N</i> -(2-hydroxypropyl)methacrylamide mono/dilactate)-Coated Liposomes for Triggered Contents Release. <i>Bioconjugate Chemistry</i> , 2007, 18, 2131-2136.	3.6	66
132	Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement. <i>Journal of Controlled Release</i> , 2022, 341, 475-486.	9.9	66
133	In vitro cellular handling and in vivo targeting of E-selectin-directed immunoconjugates and immunoliposomes used for drug delivery to inflamed endothelium. <i>Pharmaceutical Research</i> , 2003, 20, 64-72.	3.5	65
134	Constrained and UV-activatable cell-penetrating peptides for intracellular delivery of liposomes. <i>Journal of Controlled Release</i> , 2012, 164, 87-94.	9.9	65
135	Anti-angiogenic effects of liposomal prednisolone phosphate on B16 melanoma in mice. <i>Journal of Controlled Release</i> , 2006, 113, 1-8.	9.9	64
136	Hyperthermia-Induced Drug Delivery from Thermosensitive Liposomes Encapsulated in an Injectable Hydrogel for Local Chemotherapy. <i>Advanced Healthcare Materials</i> , 2014, 3, 854-859.	7.6	64
137	MPLA incorporation into DC-targeting glycoliposomes favours anti-tumour T cell responses. <i>Journal of Controlled Release</i> , 2015, 216, 37-46.	9.9	64
138	Diagnostic and therapeutic strategies for small abdominal aortic aneurysms. <i>Nature Reviews Cardiology</i> , 2011, 8, 338-347.	13.7	63
139	Differential uptake of nanoparticles by human M1 and M2 polarized macrophages: protein corona as a critical determinant. <i>Nanomedicine</i> , 2016, 11, 2889-2902.	3.3	63
140	Targeting distinct myeloid cell populations in vivo using polymers, liposomes and microbubbles. <i>Biomaterials</i> , 2017, 114, 106-120.	11.4	63
141	From design to the clinic: practical guidelines for translating cardiovascular nanomedicine. <i>Cardiovascular Research</i> , 2018, 114, 1714-1727.	3.8	63
142	Targeted Delivery of siRNA. <i>Journal of Biomedicine and Biotechnology</i> , 2006, 2006, 1-9.	3.0	62
143	Identification of Peptide Ligands for Targeting to the Blood-Brain Barrier. <i>Pharmaceutical Research</i> , 2010, 27, 673-682.	3.5	62
144	Gene Silencing Activity of siRNA Polyplexes Based on Thiolated <i>N</i> -(2-hydroxypropyl)-Trimethylated Chitosan. <i>Bioconjugate Chemistry</i> , 2010, 21, 2339-2346.	3.6	62

#	ARTICLE	IF	CITATIONS
145	Enzymosomes with surface-exposed superoxide dismutase: In vivo behaviour and therapeutic activity in a model of adjuvant arthritis. <i>Journal of Controlled Release</i> , 2007, 117, 186-195.	9.9	61
146	Angiogenic endothelium shows lactadherin-dependent phagocytosis of aged erythrocytes and apoptotic cells. <i>Blood</i> , 2008, 111, 4542-4550.	1.4	61
147	Integrin alpha 11 in the regulation of the myofibroblast phenotype: implications for fibrotic diseases. <i>Experimental and Molecular Medicine</i> , 2017, 49, e396-e396.	7.7	61
148	In Vivo Applications of PEG Liposomes: Unexpected Observations. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2001, 18, 16.	2.2	61
149	Tc-99m-PEG-Liposomes for the Evaluation of Colitis in Crohn's Disease. <i>Journal of Drug Targeting</i> , 2000, 8, 225-233.	4.4	60
150	Comparative transfection studies of human ovarian carcinoma cells in vitro, ex vivo and in vivo with poly(2-(dimethylamino)ethyl methacrylate)-based polyplexes. <i>Journal of Gene Medicine</i> , 1999, 1, 156-165.	2.8	59
151	Biodegradable Poly(2-Dimethylamino Ethylamino)Phosphazene for In Vivo Gene Delivery to Tumor Cells. Effect of Polymer Molecular Weight. <i>Pharmaceutical Research</i> , 2007, 24, 1572-1580.	3.5	59
152	Application of poly(2-(dimethylamino)ethyl methacrylate)-based polyplexes for gene transfer into human ovarian carcinoma cells. <i>International Journal of Pharmaceutics</i> , 2005, 304, 185-192.	5.2	58
153	Targeted drug delivery systems for the intracellular delivery of macromolecular drugs. <i>Drug Discovery Today</i> , 2003, 8, 482-483.	6.4	56
154	Evidence for a new mechanism behind HIFU-triggered release from liposomes. <i>Journal of Controlled Release</i> , 2013, 168, 327-333.	9.9	56
155	Inhibition of hypoxia inducible factor 1 and topoisomerase with acriflavine sensitizes perihilar cholangiocarcinomas to photodynamic therapy. <i>Oncotarget</i> , 2016, 7, 3341-3356.	1.8	56
156	Cyclodextrin as membrane protectant in spray-drying and freeze-drying of PEGylated liposomes. <i>International Journal of Pharmaceutics</i> , 2012, 438, 209-216.	5.2	55
157	MRI-assessed therapeutic effects of locally administered PLGA nanoparticles loaded with anti-inflammatory siRNA in a murine arthritis model. <i>Journal of Controlled Release</i> , 2012, 161, 772-780.	9.9	55
158	Reprogramming tumor stroma using an endogenous lipid lipoxin A4 to treat pancreatic cancer. <i>Cancer Letters</i> , 2018, 420, 247-258.	7.2	55
159	Molecular biology of epidermal growth factor receptor inhibition for cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2006, 6, 605-617.	3.1	54
160	Liposomal glucocorticoids as tumor-targeted anti-angiogenic nanomedicine in B16 melanoma-bearing mice. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2008, 111, 101-110.	2.5	54
161	Optimization of Intradermal Vaccination by DNA Tattooing in Human Skin. <i>Human Gene Therapy</i> , 2009, 20, 181-189.	2.7	54
162	Selective tumor antigen vaccine delivery to human CD169 antigen-presenting cells using ganglioside-liposomes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 27528-27539.	7.1	54

#	ARTICLE	IF	CITATIONS
163	Immunoliposomes in Vivo. <i>ImmunoMethods</i> , 1994, 4, 259-272.	0.8	53
164	Overcoming cellular multidrug resistance using classical nanomedicine formulations. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 45, 421-428.	4.0	53
165	Triggered Release of Doxorubicin from Temperature-Sensitive Poly(<i>N</i> -(2-hydroxypropyl)-methacrylamide mono/dilactate) Grafted Liposomes. <i>Biomacromolecules</i> , 2014, 15, 1002-1009.	5.4	52
166	Granzyme B-loaded, cell-selective penetrating and reduction-responsive polymersomes effectively inhibit progression of orthotopic human lung tumor in vivo. <i>Journal of Controlled Release</i> , 2018, 290, 141-149.	9.9	52
167	Contribution of Classic and Alternative Effector Pathways in Peanut-Induced Anaphylactic Responses. <i>PLoS ONE</i> , 2011, 6, e28917.	2.5	52
168	Localization of sterically stabilized liposomes in <i>Klebsiella pneumoniae</i> -infected rat lung tissue: influence of liposome characteristics. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1999, 1421, 329-339.	2.6	51
169	Therapeutic Application of Long-Circulating Liposomal Glucocorticoids in Auto-Immune Diseases and Cancer. <i>Journal of Liposome Research</i> , 2006, 16, 185-194.	3.3	51
170	Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity. <i>Journal of Controlled Release</i> , 2011, 151, 10-17.	9.9	51
171	Optimizing the therapeutic index of liposomal glucocorticoids in experimental arthritis. <i>International Journal of Pharmaceutics</i> , 2011, 416, 471-477.	5.2	51
172	MRI of ICAM-1 Upregulation After Stroke: the Importance of Choosing the Appropriate Target-Specific Particulate Contrast Agent. <i>Molecular Imaging and Biology</i> , 2013, 15, 411-422.	2.6	50
173	Glucocorticoid-loaded liposomes induce a pro-resolution phenotype in human primary macrophages to support chronic wound healing. <i>Biomaterials</i> , 2018, 178, 481-495.	11.4	50
174	Endothelial Cells at Inflammatory Sites as Target for Therapeutic Intervention. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2002, 9, 161-171.	1.7	49
175	Intravenous fate of poly(2-(dimethylamino)ethyl methacrylate)-based polyplexes. <i>European Journal of Pharmaceutical Sciences</i> , 2003, 20, 419-427.	4.0	49
176	Lanthanide-Loaded Liposomes for Multimodality Imaging and Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2006, 21, 520-527.	1.0	49
177	Complement activation by PEGylated liposomes containing prednisolone. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 49, 265-271.	4.0	49
178	Duration of ultrasound-mediated enhanced plasma membrane permeability. <i>International Journal of Pharmaceutics</i> , 2015, 482, 92-98.	5.2	49
179	Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, 35-45.	3.1	49
180	Liposomal nanomedicines in the treatment of prostate cancer. <i>Cancer Treatment Reviews</i> , 2014, 40, 578-584.	7.7	48

#	ARTICLE	IF	CITATIONS
181	Microscopic localization of PEG-liposomes in a rat model of focal infection. <i>Journal of Controlled Release</i> , 2001, 75, 347-355.	9.9	47
182	Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation. <i>Journal of Controlled Release</i> , 2010, 148, 303-310.	9.9	47
183	Disulfide-Based Poly(amido amine)s for siRNA Delivery: Effects of Structure on siRNA Complexation, Cellular Uptake, Gene Silencing and Toxicity. <i>Pharmaceutical Research</i> , 2011, 28, 1013-1022.	3.5	47
184	Applying nanomedicine in maladaptive inflammation and angiogenesis. <i>Advanced Drug Delivery Reviews</i> , 2017, 119, 143-158.	13.7	46
185	The interaction of cytostatic drugs with adsorbents in aqueous media. The potential implications for liposome preparation. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1985, 818, 343-351.	2.6	45
186	Polyplexes based on cationic polymers with strong nucleic acid binding properties. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 45, 459-466.	4.0	45
187	Thermally triggered release of a pro-osteogenic peptide from a functionalized collagen-based scaffold using thermosensitive liposomes. <i>Journal of Controlled Release</i> , 2014, 187, 158-166.	9.9	45
188	Improving Taxane-Based Chemotherapy in Castration-Resistant Prostate Cancer. <i>Trends in Pharmacological Sciences</i> , 2016, 37, 451-462.	8.7	45
189	Subcutaneous administration of superoxide dismutase entrapped in long circulating liposomes: in vivo fate and therapeutic activity in an inflammation model. <i>Pharmaceutical Research</i> , 2000, 17, 600-606.	3.5	44
190	Effect of Liposome Characteristics and Dose on the Pharmacokinetics of Liposomes Coated with Poly(amino acid)s. <i>Pharmaceutical Research</i> , 2007, 24, 2394-2401.	3.5	44
191	A systematic comparison of clinically viable nanomedicines targeting HMG-CoA reductase in inflammatory atherosclerosis. <i>Journal of Controlled Release</i> , 2017, 262, 47-57.	9.9	44
192	Liposomal Targeting of Prednisolone Phosphate to Synovial Lining Macrophages during Experimental Arthritis Inhibits M1 Activation but Does Not Favor M2 Differentiation. <i>PLoS ONE</i> , 2013, 8, e54016.	2.5	43
193	Liposomes and biotherapeutics. <i>Biotherapy (Dordrecht, Netherlands)</i> , 1991, 3, 25-42.	0.7	41
194	Localization of sterically stabilized liposomes in experimental rat <i>Klebsiella pneumoniae pneumonia</i> : dependence on circulation kinetics and presence of poly(ethylene)glycol coating. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2000, 1468, 253-261.	2.6	41
195	Long-Circulating Sterically Stabilized Liposomes in the Treatment of Infections. <i>Methods in Enzymology</i> , 2005, 391, 228-260.	1.0	41
196	Intravenously delivered glucocorticoid liposomes inhibit osteoclast activity and bone erosion in murine antigen-induced arthritis. <i>Journal of Controlled Release</i> , 2011, 152, 363-369.	9.9	41
197	Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth In Vivo. <i>Prostate</i> , 2015, 75, 815-824.	2.3	41
198	Radionuclide imaging of liposomal drug delivery. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 1231-1242.	5.0	41

#	ARTICLE	IF	CITATIONS
199	Liposomes for Intravenous Drug Targeting: Design and Applications. <i>Mini-Reviews in Medicinal Chemistry</i> , 2002, 2, 319-329.	2.4	41
200	Immunoliposomes in vivo: state of the art. <i>Advanced Drug Delivery Reviews</i> , 1988, 1, 249-266.	13.7	40
201	Docosahexaenoic acid liposomes for targeting chronic inflammatory diseases and cancer: an in vitro assessment. <i>International Journal of Nanomedicine</i> , 2016, Volume 11, 5027-5040.	6.7	40
202	Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo. <i>Acta Biomaterialia</i> , 2019, 92, 196-204.	8.3	40
203	Lipid-coated polyplexes for targeted gene delivery to ovarian carcinoma cells. <i>Cancer Gene Therapy</i> , 2001, 8, 405-413.	4.6	39
204	Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of prodrugs: comparison with the corresponding antibody-enzyme conjugate. <i>Pharmaceutical Research</i> , 2003, 20, 423-428.	3.5	39
205	Tyrosine kinase inhibitor BIBF1120 ameliorates inflammation, angiogenesis and fibrosis in CCl4-induced liver fibrogenesis mouse model. <i>Scientific Reports</i> , 2017, 7, 44545.	3.3	39
206	Gene silencing activity of siRNA polyplexes based on biodegradable polymers. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2011, 77, 450-457.	4.3	38
207	Image-guided drug delivery: preclinical applications and clinical translation. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 1203-1207.	5.0	38
208	Increase of intracellular cisplatin levels and radiosensitization by ultrasound in combination with microbubbles. <i>Journal of Controlled Release</i> , 2016, 238, 157-165.	9.9	38
209	Transporting silence: Design of carriers for siRNA to angiogenic endothelium. <i>Journal of Controlled Release</i> , 2005, 109, 5-14.	9.9	37
210	Cytosolic Delivery of Liposomally Targeted Proteins Induced by Photochemical Internalization. <i>Pharmaceutical Research</i> , 2007, 24, 2040-2047.	3.5	37
211	Antitumor activity and tumor localization of liposomal glucocorticoids in B16 melanoma-bearing mice. <i>Journal of Controlled Release</i> , 2008, 127, 131-136.	9.9	37
212	Pharmaceutical development and preclinical evaluation of a GMP-grade anti-inflammatory nanotherapy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 1133-1140.	3.3	37
213	Tailoring the physicochemical properties of core-crosslinked polymeric micelles for pharmaceutical applications. <i>Journal of Controlled Release</i> , 2016, 244, 314-325.	9.9	37
214	Therapeutic inhibition of spleen tyrosine kinase in inflammatory macrophages using PLGA nanoparticles for the treatment of non-alcoholic steatohepatitis. <i>Journal of Controlled Release</i> , 2018, 288, 227-238.	9.9	37
215	The hepatic lipidome: From basic science to clinical translation. <i>Advanced Drug Delivery Reviews</i> , 2020, 159, 180-197.	13.7	37
216	Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): optimization of prodrug activating capacity. <i>Pharmaceutical Research</i> , 1996, 13, 604-610.	3.5	36

#	ARTICLE	IF	CITATIONS
217	Theranostic Systems and Strategies for Monitoring Nanomedicine-Mediated Drug Targeting. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 609-622.	1.6	36
218	Comparison of Polymeric siRNA Nanocarriers in a Murine LPS-Activated Macrophage Cell Line: Gene Silencing, Toxicity and Off-Target Gene Expression. <i>Pharmaceutical Research</i> , 2012, 29, 669-682.	3.5	36
219	Complement activation in vitro and reactogenicity of low-molecular weight dextran-coated SPIONs in the pig CARPA model: Correlation with physicochemical features and clinical information. <i>Journal of Controlled Release</i> , 2018, 270, 268-274.	9.9	36
220	Liposome-induced hypersensitivity reactions: Risk reduction by design of safe infusion protocols in pigs. <i>Journal of Controlled Release</i> , 2019, 309, 333-338.	9.9	36
221	Selective transferrin coating as a facile strategy to fabricate BBB-permeable and targeted vesicles for potent RNAi therapy of brain metastatic breast cancer in vivo. <i>Journal of Controlled Release</i> , 2021, 337, 521-529.	9.9	36
222	Enhanced engraftment of human cells in RAG2/ β 2m double-knockout mice after treatment with CL2MDP liposomes. <i>Experimental Hematology</i> , 2004, 32, 1118-1125.	0.4	35
223	Enzymatic Degradation of Liposome-Grafted Poly(hydroxyethyl L-glutamine). <i>Bioconjugate Chemistry</i> , 2005, 16, 767-774.	3.6	35
224	In situ Delivery of Antigen to DC-SIGN + CD14 + Dermal Dendritic Cells Results in Enhanced CD8 + T-Cell Responses. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2228-2236.	0.7	35
225	Fibroblast growth factor 2 conjugated superparamagnetic iron oxide nanoparticles (FGF2-SPIONs) ameliorate hepatic stellate cells activation in vitro and acute liver injury in vivo. <i>Journal of Controlled Release</i> , 2020, 328, 640-652.	9.9	35
226	MRI evaluation of the antitumor activity of paramagnetic liposomes loaded with prednisolone phosphate. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 45, 436-441.	4.0	34
227	Cyclic RGD-Functionalized and Disulfide-Crosslinked Iodine-Rich Polymersomes as a Robust and Smart Theranostic Agent for Targeted CT Imaging and Chemotherapy of Tumor. <i>Theranostics</i> , 2019, 9, 8061-8072.	10.0	34
228	Immunoglobulin free light chains are biomarkers of poor prognosis in basal-like breast cancer and are potential targets in tumor-associated inflammation. <i>Oncotarget</i> , 2014, 5, 3159-3167.	1.8	34
229	Lymphatic Uptake and Biodistribution of Liposomes after Subcutaneous Injection I. Influence of the Anatomical Site of Injection. <i>Journal of Liposome Research</i> , 1997, 7, 85-99.	3.3	33
230	Strategies for cytosolic delivery of liposomal macromolecules. <i>International Journal of Pharmaceutics</i> , 2005, 298, 305-309.	5.2	33
231	DC-SIGN mediated antigen-targeting using glycan-modified liposomes: Formulation considerations. <i>International Journal of Pharmaceutics</i> , 2011, 416, 426-432.	5.2	33
232	Combined treatment with recombinant tissue plasminogen activator and dexamethasone phosphate-containing liposomes improves neurological outcome and restricts lesion progression after embolic stroke in rats. <i>Journal of Neurochemistry</i> , 2012, 123, 65-74.	3.9	33
233	Evaluation of subconjunctival liposomal steroids for the treatment of experimental uveitis. <i>Scientific Reports</i> , 2018, 8, 6604.	3.3	33
234	Cancer nanomedicine meets immunotherapy: opportunities and challenges. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 954-958.	6.1	33

#	ARTICLE	IF	CITATIONS
235	CD169 Defines Activated CD14+ Monocytes With Enhanced CD8+ T Cell Activation Capacity. <i>Frontiers in Immunology</i> , 2021, 12, 697840.	4.8	33
236	Sterically stabilized amphotericin B-liposomes: toxicity and biodistribution in mice. <i>Journal of Controlled Release</i> , 1995, 37, 123-129.	9.9	32
237	Design of immunoliposomes directed against human ovarian carcinoma. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1995, 1235, 126-139.	2.6	32
238	Investigation into the Role of Tumor-Associated Macrophages in the Antitumor Activity of Doxil. <i>Pharmaceutical Research</i> , 2008, 25, 1948-1955.	3.5	32
239	Liposomal nanomedicines as anticancer therapeutics: Beyond targeting tumor cells. <i>International Journal of Pharmaceutics</i> , 2008, 364, 258-264.	5.2	32
240	A method for quantifying cellular uptake of fluorescently labeled siRNA. <i>Journal of Controlled Release</i> , 2010, 148, 106-109.	9.9	32
241	Liposomes as carriers for colchicine-derived prodrugs: Vascular disrupting nanomedicines with tailorable drug release kinetics. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 45, 429-435.	4.0	32
242	Liposomal Treatment of Experimental Arthritis Can Be Monitored Noninvasively with a Radiolabeled Anti- α 1(Fib) Fibroblast Activation Protein Antibody. <i>Journal of Nuclear Medicine</i> , 2017, 58, 151-155.	5.0	32
243	Coformulated N-Octanoyl-glucosylceramide Improves Cellular Delivery and Cytotoxicity of Liposomal Doxorubicin. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 315, 704-710.	2.5	31
244	Superoxide Dismutase Enzymosomes: Carrier Capacity Optimization, in Vivo Behaviour and Therapeutic Activity. <i>Pharmaceutical Research</i> , 2015, 32, 91-102.	3.5	31
245	Anti-microRNA targeting using peptide-based nanocomplexes to inhibit differentiation of human pancreatic stellate cells. <i>Nanomedicine</i> , 2017, 12, 1369-1384.	3.3	31
246	E-selectin targeted immunoliposomes for rapamycin delivery to activated endothelial cells. <i>International Journal of Pharmaceutics</i> , 2018, 548, 759-770.	5.2	31
247	γ electron-stabilized polymeric micelles potentiate docetaxel therapy in advanced-stage gastrointestinal cancer. <i>Biomaterials</i> , 2021, 266, 120432.	11.4	31
248	Novel developments in liposomal delivery of peptides and proteins. <i>Journal of Controlled Release</i> , 1995, 36, 19-24.	9.9	30
249	Therapeutic Efficacy of Liposome-Encapsulated Gentamicin in Rat <i>Klebsiella pneumoniae</i> Pneumonia in Relation to Impaired Host Defense and Low Bacterial Susceptibility to Gentamicin. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 464-470.	3.2	30
250	CD134 as target for specific drug delivery to auto-aggressive CD4+ T cells in adjuvant arthritis. <i>Arthritis Research</i> , 2005, 7, R604.	2.0	30
251	A novel approach for the intravenous delivery of leuprolide using core-cross-linked polymeric micelles. <i>Journal of Controlled Release</i> , 2015, 205, 98-108.	9.9	30
252	Influence of cholesterol inclusion on the doxorubicin release characteristics of lysolipid-based thermosensitive liposomes. <i>International Journal of Pharmaceutics</i> , 2018, 548, 778-782.	5.2	30

#	ARTICLE	IF	CITATIONS
253	FGF2 engineered SPIONs attenuate tumor stroma and potentiate the effect of chemotherapy in 3D heterospheroidal model of pancreatic tumor. <i>Nanotheranostics</i> , 2020, 4, 26-39.	5.2	30
254	Optical imaging of the whole-body to cellular biodistribution of clinical-stage PEG-b-HPMA-based core-crosslinked polymeric micelles. <i>Journal of Controlled Release</i> , 2020, 328, 805-816.	9.9	30
255	Multimodal and multiscale optical imaging of nanomedicine delivery across the blood-brain barrier upon sonopermeation. <i>Theranostics</i> , 2020, 10, 1948-1959.	10.0	30
256	Imaging Experimental Intraabdominal Abscesses With ^{99m} Tc-PEG Liposomes and ^{99m} Tc-HYNIC IgG. <i>Annals of Surgery</i> , 1999, 229, 551-557.	4.2	30
257	Targeting liposomes to tumor endothelial cells for neutron capture therapy. <i>Applied Radiation and Isotopes</i> , 2004, 61, 963-967.	1.5	29
258	Reprint of "Nanobody $\hat{\epsilon}$ " Shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting". <i>Journal of Controlled Release</i> , 2011, 153, 93-102.	9.9	29
259	Trends in polymeric delivery of nucleic acids to tumors. <i>Journal of Controlled Release</i> , 2013, 170, 209-218.	9.9	29
260	Comparison of pharmaceutical nanoformulations for curcumin: Enhancement of aqueous solubility and carrier retention. <i>International Journal of Pharmaceutics</i> , 2016, 506, 407-413.	5.2	29
261	Histidine-rich glycoprotein-induced vascular normalization improves EPR-mediated drug targeting to and into tumors. <i>Journal of Controlled Release</i> , 2018, 282, 25-34.	9.9	29
262	Nanomedicine at the crossroads $\hat{\epsilon}$ A quick guide for IVVC. <i>Advanced Drug Delivery Reviews</i> , 2021, 179, 113829.	13.7	29
263	Engineered Relaxin as theranostic nanomedicine to diagnose and ameliorate liver cirrhosis. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 17, 106-118.	3.3	28
264	Erythrophagocytosis by angiogenic endothelial cells is enhanced by loss of erythrocyte deformability. <i>Experimental Hematology</i> , 2010, 38, 282-291.	0.4	27
265	Safety of glucocorticoids can be improved by lower yet still effective dosages of liposomal steroid formulations in murine antigen-induced arthritis: Comparison of prednisolone with budesonide. <i>International Journal of Pharmaceutics</i> , 2011, 416, 493-498.	5.2	27
266	Attaching the phage display-selected GLA peptide to liposomes: Factors influencing target binding. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 45, 330-335.	4.0	27
267	Human Regulatory T Cells Do Not Suppress the Antitumor Immunity in the Bone Marrow: A Role for Bone Marrow Stromal Cells in Neutralizing Regulatory T Cells. <i>Clinical Cancer Research</i> , 2013, 19, 1467-1475.	7.0	27
268	Liposomal dexamethasone inhibits tumor growth in an advanced human-mouse hybrid model of multiple myeloma. <i>Journal of Controlled Release</i> , 2019, 296, 232-240.	9.9	27
269	Recognition and clearance of methoxypoly(ethyleneglycol)2000-grafted liposomes by macrophages with enhanced phagocytic capacity Implications in experimental and clinical oncology. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2001, 1526, 227-229.	2.4	26
270	Synthetic vehicles for DNA vaccination. <i>Journal of Drug Targeting</i> , 2010, 18, 1-14.	4.4	26

#	ARTICLE	IF	CITATIONS
271	Imaging the Efficacy of Anti-Inflammatory Liposomes in a Rabbit Model of Atherosclerosis by Non-Invasive Imaging. <i>Methods in Enzymology</i> , 2012, 508, 211-228.	1.0	26
272	Inhibition of Tumor Growth by Targeted Anti-EGFR/IGF-1R Nanobullets Depends on Efficient Blocking of Cell Survival Pathways. <i>Molecular Pharmaceutics</i> , 2013, 10, 3717-3727.	4.6	26
273	TARGETED LIPOSOMES FOR DELIVERY OF PROTEIN-BASED DRUGS INTO THE CYTOPLASM OF TUMOR CELLS. <i>Journal of Liposome Research</i> , 2002, 12, 57-65.	3.3	25
274	Plasmid CpG Depletion Improves Degree and Duration of Tumor Gene Expression After Intravenous Administration of Polyplexes. <i>Pharmaceutical Research</i> , 2008, 25, 1654-1662.	3.5	25
275	Alginate Microspheres Containing Temperature Sensitive Liposomes (TSL) for MR-Guided Embolization and Triggered Release of Doxorubicin. <i>PLoS ONE</i> , 2015, 10, e0141626.	2.5	25
276	In situ Delivery of Tumor Antigen and Adjuvant-Loaded Liposomes Boosts Antigen-Specific T-Cell Responses by Human Dermal Dendritic Cells. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2697-2704.	0.7	25
277	Locoregional cancer therapy using polymer-based drug depots. <i>Drug Discovery Today</i> , 2016, 21, 640-647.	6.4	25
278	Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes. <i>FEBS Letters</i> , 1996, 399, 232-236.	2.8	24
279	Enzyme-induced shedding of a poly(amino acid)-coating triggers contents release from dioleoyl phosphatidylethanolamine liposomes. <i>International Journal of Pharmaceutics</i> , 2008, 355, 108-113.	5.2	24
280	Eradication of Medullary Multiple Myeloma by CD4+ Cytotoxic Human T Lymphocytes Directed at a Single Minor Histocompatibility Antigen. <i>Clinical Cancer Research</i> , 2010, 16, 5481-5488.	7.0	24
281	A polymeric colchicinoid prodrug with reduced toxicity and improved efficacy for vascular disruption in cancer therapy. <i>International Journal of Nanomedicine</i> , 2011, 6, 2697.	6.7	23
282	Comparison of three remote radiolabelling methods for long-circulating liposomes. <i>Journal of Controlled Release</i> , 2015, 220, 239-244.	9.9	23
283	[¹⁸ F]FDG PET/CT imaging to monitor the therapeutic effect of liposome-encapsulated prednisolone in experimental rheumatoid arthritis. <i>Journal of Controlled Release</i> , 2015, 209, 20-26.	9.9	23
284	Targeting influenza virosomes to ovarian carcinoma cells. <i>FEBS Letters</i> , 2001, 509, 71-76.	2.8	22
285	Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells. <i>International Journal of Nanomedicine</i> , 2012, 7, 417.	6.7	22
286	Imaging fibroblast activation protein to monitor therapeutic effects of neutralizing interleukin-22 in collagen-induced arthritis. <i>Rheumatology</i> , 2018, 57, 737-747.	1.9	22
287	Liver fibrosis affects the targeting properties of drug delivery systems to macrophage subsets in vivo. <i>Biomaterials</i> , 2019, 206, 49-60.	11.4	22
288	Multimodal Positron Emission Tomography Imaging to Quantify Uptake of ⁸⁹ Zr-Labeled Liposomes in the Atherosclerotic Vessel Wall. <i>Bioconjugate Chemistry</i> , 2020, 31, 360-368.	3.6	22

#	ARTICLE	IF	CITATIONS
289	Interaction of Recombinant Interleukin-2 with Liposomal Bilayers. <i>Journal of Pharmaceutical Sciences</i> , 1998, 87, 707-714.	3.3	21
290	Intervention in growth factor activated signaling pathways by renally targeted kinase inhibitors. <i>Journal of Controlled Release</i> , 2008, 132, 200-207.	9.9	21
291	Utility of Targeted Glucocorticoids in Cancer Therapy. <i>Journal of Liposome Research</i> , 2008, 18, 47-57.	3.3	21
292	Biodegradable, Cationic Methacrylamide-Based Polymers for Gene Delivery to Ovarian Cancer Cells in Mice. <i>Molecular Pharmaceutics</i> , 2008, 5, 349-357.	4.6	21
293	Cationic polymeric gene delivery of β -glucuronidase for doxorubicin prodrug therapy. <i>Journal of Gene Medicine</i> , 1999, 1, 407-414.	2.8	20
294	Critical factors in the development of tumor-targeted anti-inflammatory nanomedicines. <i>Journal of Controlled Release</i> , 2012, 160, 232-238.	9.9	20
295	Ocular pharmacoscintigraphic and aqueous humoral drug availability of ganciclovir-loaded mucoadhesive nanoparticles in rabbits. <i>European Journal of Nanomedicine</i> , 2013, 5, .	0.6	20
296	Alginate microgels loaded with temperature sensitive liposomes for magnetic resonance imageable drug release and microgel visualization. <i>European Polymer Journal</i> , 2015, 72, 620-631.	5.4	20
297	Head-to-Head Comparison of Anti-Inflammatory Performance of Known Natural Products In Vitro. <i>PLoS ONE</i> , 2016, 11, e0155325.	2.5	20
298	Liposomal Nanovaccine Containing β -Galactosylceramide and Ganglioside GM3 Stimulates Robust CD8+ T Cell Responses via CD169+ Macrophages and cDC1. <i>Vaccines</i> , 2021, 9, 56.	4.4	20
299	ICS-283: a system for targeted intravenous delivery of siRNA. <i>Expert Opinion on Drug Delivery</i> , 2006, 3, 445-454.	5.0	19
300	Tumor vasculature as target for therapeutic intervention. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1321-1338.	4.1	19
301	Liposome-mediated peptide loading of MHC-DR molecules in vivo. <i>FEBS Letters</i> , 1997, 409, 91-95.	2.8	18
302	HPMA-based polymer therapeutics improve the efficacy of surgery, of radiotherapy and of chemotherapy combinations. <i>Nanomedicine</i> , 2010, 5, 1501-1523.	3.3	18
303	Development of a Cell-Selective and Intrinsically Active Multikinase Inhibitor Bioconjugate. <i>Bioconjugate Chemistry</i> , 2011, 22, 540-545.	3.6	18
304	Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of anticancer prodrugs. <i>Advanced Drug Delivery Reviews</i> , 1997, 24, 225-231.	13.7	17
305	LIGAND-TARGETED LIPOSOMES DIRECTED AGAINST PATHOLOGICAL VASCULATURE. <i>Journal of Liposome Research</i> , 2002, 12, 129-135.	3.3	17
306	Radiolabeling of Liposomes for Scintigraphic Imaging. <i>Methods in Enzymology</i> , 2003, 373, 234-248.	1.0	17

#	ARTICLE	IF	CITATIONS
307	New Insights into the HIFU-Triggered Release from Polymeric Micelles. <i>Langmuir</i> , 2013, 29, 9483-9490.	3.5	17
308	PEG-pHPMAm-based polymeric micelles loaded with doxorubicin-prodrugs in combination antitumor therapy with oncolytic vaccinia viruses. <i>Polymer Chemistry</i> , 2014, 5, 1674-1681.	3.9	17
309	Fluorophore labeling of core-crosslinked polymeric micelles for multimodal <i>in vivo</i> and <i>ex vivo</i> optical imaging. <i>Nanomedicine</i> , 2015, 10, 1111-1125.	3.3	17
310	Shelf-Life Evaluation and Lyophilization of PBCA-Based Polymeric Microbubbles. <i>Pharmaceutics</i> , 2019, 11, 433.	4.5	17
311	Clinical outcome measures and scoring systems used in prospective studies of port wine stains: A systematic review. <i>PLoS ONE</i> , 2020, 15, e0235657.	2.5	17
312	Lyophilization stabilizes clinical-stage core-crosslinked polymeric micelles to overcome cold chain supply challenges. <i>Biotechnology Journal</i> , 2021, 16, e2000212.	3.5	17
313	Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders. <i>Advanced Drug Delivery Reviews</i> , 2021, 175, 113831.	13.7	17
314	TG101348, a selective JAK2 antagonist, ameliorates hepatic fibrogenesis <i>in vivo</i> . <i>FASEB Journal</i> , 2019, 33, 9466-9475.	0.5	16
315	Ligand-targeted Particulate Nanomedicines Undergoing Clinical Evaluation: Current Status. <i>Fundamental Biomedical Technologies</i> , 2016, , 163-200.	0.2	16
316	Role of spleen tyrosine kinase in liver diseases. <i>World Journal of Gastroenterology</i> , 2020, 26, 1005-1019.	3.3	16
317	Administration of prednisolone phosphate liposomes reduces wound contraction in a rat partial-thickness wound model. <i>Wound Repair and Regeneration</i> , 2006, 14, 602-607.	3.0	15
318	Therapeutic Nanomedicine: Cross linked micelles with transiently linked drugs – a versatile drug delivery system. <i>European Journal of Nanomedicine</i> , 2010, 3, 19-24.	0.6	15
319	Optimization of Liposomes for Antigen Targeting to Splenic CD169+ Macrophages. <i>Pharmaceutics</i> , 2020, 12, 1138.	4.5	15
320	Alveolar macrophages have a dual role in a rat model for trimellitic anhydride-induced occupational asthma. <i>Toxicology and Applied Pharmacology</i> , 2006, 211, 20-29.	2.8	14
321	Liposomal prednisolone inhibits tumor growth in a spontaneous mouse mammary carcinoma model. <i>Journal of Controlled Release</i> , 2016, 243, 243-249.	9.9	14
322	Lipogels responsive to near-infrared light for the triggered release of therapeutic agents. <i>Acta Biomaterialia</i> , 2017, 61, 54-65.	8.3	14
323	Therapeutic Efficacy of Novel Antimicrobial Peptide AA139-Nanomedicines in a Multidrug-Resistant <i>Klebsiella pneumoniae</i> Pneumonia-Septicemia Model in Rats. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	14
324	¹ H NMR Spectroscopy as a Tool for Determining the Composition of Poly(hydroxyethyl-L-asparagine)-Coated Liposomes. <i>Bioconjugate Chemistry</i> , 2006, 17, 860-864.	3.6	13

#	ARTICLE	IF	CITATIONS
325	Alveolar macrophages suppress non-specific inflammation caused by inhalation challenge with trimellitic anhydride conjugated to albumin. <i>Archives of Toxicology</i> , 2006, 80, 561-571.	4.2	13
326	Targeted Delivery of Anti-Inflammatory Agents to Tumors. <i>Current Pharmaceutical Design</i> , 2009, 15, 1825-1843.	1.9	13
327	Multi-parametric assessment of the anti-angiogenic effects of liposomal glucocorticoids. <i>Angiogenesis</i> , 2011, 14, 143-153.	7.2	13
328	Nanoclusters of Iron Oxide: Effect of Core Composition on Structure, Biocompatibility, and Cell Labeling Efficacy. <i>Bioconjugate Chemistry</i> , 2012, 23, 941-950.	3.6	13
329	Antibiotic-nanomedicines: facing the challenge of effective treatment of antibiotic-resistant respiratory tract infections. <i>Future Microbiology</i> , 2018, 13, 1683-1692.	2.0	13
330	Development and characterization of liposomal formulation of bortezomib. <i>International Journal of Pharmaceutics: X</i> , 2019, 1, 100011.	1.6	13
331	High-resolution 3D visualization of nanomedicine distribution in tumors. <i>Theranostics</i> , 2020, 10, 880-897.	10.0	13
332	Processing of Doxorubicin-Containing Liposomes by Liver Macrophages in Vitro. <i>Journal of Liposome Research</i> , 1989, 1, 195-210.	3.3	12
333	Opportunities in targeted drug delivery to Kupffer cells: delivery of immunomodulators to Kupffer cells-activation of tumoricidal properties. <i>Advanced Drug Delivery Reviews</i> , 1995, 17, 21-30.	13.7	12
334	Synthetic delivery systems for intravenous administration of nucleic acids. <i>Nanomedicine</i> , 2007, 2, 169-181.	3.3	12
335	Nanomedicine formulations for combination therapies. <i>Nano Reviews</i> , 2010, 1, 5705.	3.7	12
336	Macromolecular nanotheranostics for multimodal anticancer therapy. <i>Nanoscale</i> , 2011, 3, 4022.	5.6	12
337	A paradigm shift in cancer nanomedicine: from traditional tumor targeting to leveraging the immune system. <i>Drug Discovery Today</i> , 2021, 26, 1482-1489.	6.4	12
338	Development of a routine analysis method for liposome encapsulated recombinant interleukin-2. <i>Biomedical Applications</i> , 1998, 716, 285-291.	1.7	11
339	Therapeutic efficacy of liposomal gentamicin in clinically relevant rat models. <i>International Journal of Pharmaceutics</i> , 2001, 214, 103-105.	5.2	11
340	siRNA-mediated inhibition of angiogenesis. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 359-368.	3.1	11
341	Liposomal Targeting of Angiogenic Vasculature. <i>Current Drug Delivery</i> , 2005, 2, 363-368.	1.6	11
342	Quantitative Assessment of Human T Lymphocytes in RAG2 ^Δ /Δ ⁺ Mice: The Impact of Ex Vivo Manipulation on In Vivo Functionality. <i>Experimental Hematology</i> , 2007, 35, 117-127.	0.4	11

#	ARTICLE	IF	CITATIONS
343	Liposomal doxorubicin: the good, the bad and the not-so-ugly. <i>Journal of Drug Targeting</i> , 2016, 24, 765-767.	4.4	11
344	Systematic evaluation of design features enables efficient selection of \hat{I} electron-stabilized polymeric micelles. <i>International Journal of Pharmaceutics</i> , 2020, 584, 119409.	5.2	11
345	Targeted delivery of diphtheria toxin via immunoliposomes: efficient antitumor activity in the presence of inactivating anti-diphtheria toxin antibodies. <i>FEBS Letters</i> , 1996, 395, 245-250.	2.8	10
346	Liposomes: The Science and the Regulatory Landscape. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2015, , 77-106.	0.6	10
347	A review of the clinical applications of drug delivery systems for the treatment of ocular anterior segment inflammation. <i>British Journal of Ophthalmology</i> , 2021, 105, 1617-1622.	3.9	10
348	Ultrasound and Microbubbles for the Treatment of Ocular Diseases: From Preclinical Research towards Clinical Application. <i>Pharmaceutics</i> , 2021, 13, 1782.	4.5	10
349	Site-specific pharmaco-laser therapy: A novel treatment modality for refractory port wine stains. <i>Journal of Clinical and Translational Research</i> , 2019, 5, 1-24.	0.3	10
350	Lyophilization of TC-99m-Hynic Labeled Peg-Liposomes. <i>Journal of Liposome Research</i> , 2000, 10, 117-129.	3.3	9
351	Targeting cellular and microenvironmental multidrug resistance. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 1199-1202.	5.0	9
352	Preclinical evaluation of thermosensitive poly(N-(2-hydroxypropyl) methacrylamide) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 387 Td (mono <i>Pharmaceutics</i> , 2018, 550, 190-199.	5.2	9
353	Scale-Up of the Manufacturing Process To Produce Docetaxel-Loaded mPEG- <i>b</i> -p(HPMA-Bz) Block Copolymer Micelles for Pharmaceutical Applications. <i>Organic Process Research and Development</i> , 2019, 23, 2707-2715.	2.7	9
354	Apoptosis-inducing peptide loaded in PLGA nanoparticles induces anti-tumor effects in vivo. <i>International Journal of Pharmaceutics</i> , 2020, 585, 119535.	5.2	9
355	Lyophilization Preserves the Intrinsic Cardioprotective Activity of Bioinspired Cell-Derived Nanovesicles. <i>Pharmaceutics</i> , 2021, 13, 1052.	4.5	9
356	Targeting of Antibiotics in Bacterial Infections Using Pegylated Long-Circulating Liposomes. <i>Journal of Liposome Research</i> , 2000, 10, 513-521.	3.3	8
357	Anginex lipoplexes for delivery of anti-angiogenic siRNA. <i>International Journal of Pharmaceutics</i> , 2014, 472, 175-184.	5.2	8
358	Multiple pathway assessment to predict anti-atherogenic efficacy of drugs targeting macrophages in atherosclerotic plaques. <i>Vascular Pharmacology</i> , 2016, 82, 51-59.	2.1	8
359	LIPOSOME-ENABLED SYNERGISTIC INTERACTION OF ANTIMICROBIAL AGENTS. <i>Journal of Liposome Research</i> , 2002, 12, 121-127.	3.3	7
360	Liposomes targeting tumour stromal cells. <i>Molecular Membrane Biology</i> , 2010, 27, 328-340.	2.0	7

#	ARTICLE	IF	CITATIONS
361	A novel approach to identify non-palpable breast lesions combining fluorescent liposomes and magnetic resonance-guided high intensity focused ultrasound-triggered release. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2011, 77, 458-464.	4.3	7
362	Hepatitis C Virus Nonstructural 3/4A Protein Dampens Inflammation and Contributes to Slow Fibrosis Progression during Chronic Fibrosis In Vivo. <i>PLoS ONE</i> , 2015, 10, e0128466.	2.5	7
363	Development of a tumor tissue-mimicking model with endothelial cell layer and collagen gel for evaluating drug penetration. <i>International Journal of Pharmaceutics</i> , 2015, 482, 118-122.	5.2	7
364	High systemic availability of core-crosslinked polymeric micelles after subcutaneous administration. <i>International Journal of Pharmaceutics</i> , 2016, 514, 112-120.	5.2	7
365	Critical evaluation of quantification methods for oligonucleotides formulated in lipid nanoparticles. <i>International Journal of Pharmaceutics</i> , 2018, 548, 793-802.	5.2	7
366	Environmental impact of switching from the synthetic glucocorticoid prednisolone to the natural alkaloid berberine. <i>PLoS ONE</i> , 2018, 13, e0199095.	2.5	7
367	Treatment Outcome Measurement Instruments for Port Wine Stains: A Systematic Review of Their Measurement Properties. <i>Dermatology</i> , 2021, 237, 416-432.	2.1	7
368	Mimicking Pathogens to Augment the Potency of Liposomal Cancer Vaccines. <i>Pharmaceutics</i> , 2021, 13, 954.	4.5	7
369	TAT-Peptide Modified Liposomes: Preparation, Characterization, and Cellular Interaction. <i>Methods in Molecular Biology</i> , 2010, 605, 349-359.	0.9	7
370	Incorporation of Toll-Like Receptor Ligands and Inflammasome Stimuli in GM3 Liposomes to Induce Dendritic Cell Maturation and T Cell Responses. <i>Frontiers in Immunology</i> , 2022, 13, 842241.	4.8	7
371	Targeting of peptide and protein drugs. <i>European Journal of Pharmaceutical Sciences</i> , 1994, 2, 17-18.	4.0	6
372	Tumor cell and tumor vasculature targeted liposomes for neutron capture therapy. <i>Radiochimica Acta</i> , 2005, 93, 589-593.	1.2	6
373	Targeting the retinal microcirculation to treat diabetic sight problems. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 1493-1502.	3.4	6
374	Preparation and characterization of liposomal formulations of neurotensin-degrading enzyme inhibitors. <i>International Journal of Pharmaceutics</i> , 2011, 416, 448-452.	5.2	6
375	Application of cultured human regulatory T cells requires preclinical in vivo evaluation. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 852-855.e3.	2.9	6
376	Hybrid Materials: Theranostic USPIO-Loaded Microbubbles for Mediating and Monitoring Blood-Brain Barrier Permeation (<i>Adv. Funct. Mater.</i> 1/2015). <i>Advanced Functional Materials</i> , 2015, 25, 2-2.	14.9	6
377	The Effect of Microbubble-Assisted Ultrasound on Molecular Permeability across Cell Barriers. <i>Pharmaceutics</i> , 2022, 14, 494.	4.5	6
378	Complete Tumor Regression by Liposomal Bortezomib in a Humanized Mouse Model of Multiple Myeloma. <i>HemaSphere</i> , 2020, 4, e463.	2.7	5

#	ARTICLE	IF	CITATIONS
379	Liposomes for Local Sustained Drug Release. , 2000, , 137-180.		5
380	Photodynamic Therapy Targeting Macrophages Using IRDye700DX-Liposomes Decreases Experimental Arthritis Development. <i>Pharmaceutics</i> , 2021, 13, 1868.	4.5	5
381	The Design of a Pharmaceuttically Acceptable Liposomal Formulation of Recombinant Interleukin-2 (Ril-2) for Locoregional Anticancer Immunotherapy. <i>Journal of Liposome Research</i> , 1999, 9, 313-329.	3.3	4
382	Hemocompatibility Assessment of two siRNA Nanocarrier Formulations. <i>Pharmaceutical Research</i> , 2014, 31, 3127-3135.	3.5	4
383	Absolute MR thermometry using nanocarriers. <i>Contrast Media and Molecular Imaging</i> , 2014, 9, 283-290.	0.8	4
384	Distribution of technetium-99m PEG-liposomes during oligofructose-induced laminitis development in horses. <i>Veterinary Journal</i> , 2015, 206, 218-225.	1.7	4
385	Long-circulating liposomes for i.v. targeted delivery of glucocorticoids in arthritis. <i>Cellular and Molecular Biology Letters</i> , 2002, 7, 291-2.	7.0	4
386	Liposomal Delivery of Peptides and Proteins. <i>Journal of Liposome Research</i> , 1995, 5, 481-489.	3.3	3
387	Liposomal drug delivery system for anti-inflammatory treatment after cataract surgery: a phase I/II clinical trial. <i>Drug Delivery and Translational Research</i> , 2022, 12, 7-14.	5.8	3
388	Neovascular Age-Related Macular Degeneration. <i>BioDrugs</i> , 2011, 25, 171-189.	4.6	2
389	In Vivo Assessment of Thermosensitive Liposomes for the Treatment of Port Wine Stains by Antifibrinolytic Site-Specific Pharmaco-Laser Therapy. <i>Pharmaceutics</i> , 2020, 12, 591.	4.5	2
390	Radiolabeling of Liposomes for Scintigraphic Imaging. , 2006, , 169-185.		2
391	siRNA as a new drug: intellectual property. <i>Expert Opinion on Therapeutic Patents</i> , 2005, 15, 141-152.	5.0	1
392	Therapeutic nanomedicine: Liposomal corticosteroid as targeted antiinflammatory nanomedicine. <i>European Journal of Nanomedicine</i> , 2008, 1, .	0.6	1
393	Longâ€Circulating and Passively Tumorâ€Ctargeted Polymerâ€CDrug Conjugates Improve the Efficacy and Reduce the Toxicity of Radiochemotherapy. <i>Advanced Engineering Materials</i> , 2010, 12, B413.	3.5	1
394	The role of thromboxane A2 in complement activation-related pseudoallergy. <i>European Journal of Nanomedicine</i> , 2017, 9, .	0.6	1
395	Src kinase as a potential therapeutic target in nonâ€Calcoholic and alcoholic steatohepatitis. <i>Clinical and Translational Discovery</i> , 2022, 2, .	0.5	1
396	Stealthâ„¢ Therapeutic Systems: Rationale and Strategies. , 1998, , 25-34.		0

#	ARTICLE	IF	CITATIONS
397	Use of Radiolabeled Liposomes for Imaging of Infection and Inflammation. , 2008, , 237-251.		0
398	Bimodal Liposomes and Paramagnetic QD-Micelles for Multimodality Molecular Imaging of Tumor Angiogenesis. , 2008, , 487-512.		0